Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.

Andreas KronbichlerJulia KerschbaumSeerapani GopaluniJoanna TieuFederico AlbericiRachel Bronwen JonesRona M SmithDavid R W Jayne

Published in: Annals of the rheumatic diseases (2018)

We found severe infections in one quarter of patients with AAV receiving rituximab. Trimethoprim-sulfamethoxazole prophylaxis reduced the risk, while especially bronchiectasis and endobronchial involvement are risk factors for severe respiratory infections.

Keyphrases

early onset
diffuse large b cell lymphoma
cystic fibrosis
hodgkin lymphoma
drug induced
antibiotic resistance genes
wastewater treatment